Notably, the response rate did not differ by donor type (haplo-identical, mismatched unrelated, or fully matched unrelated or related), immunosuppression status (ongoing treatment with steroids, ruxolitinib, or cyclosporine), presence of active acute or chronic GVHD, or immunological recovery (total, CD8 and CD4 T, B and NK lymphocyte counts) at the time of vaccination (Table 1). This evidence concerns the gene CD8A and chronic graft versus host disease.